A Systematic Review and Meta-Analysis: Safety and Efficacy of Cediranib in the Treatment of Cancer Patients

Table 2

Grade ≥3 adverse events.

	Studies	Cediranib- containing therapy	Control	RR (95% CI)	value	I^2 (%)
Fatigue	12	271 of 2228	116 of 1754	1.80 (1.46–2.23)	<0.001	0.0	Fixed
Diarrhea	12	311 of 2228	80 of 1783	3.11 (2.46–3.95)	<0.001	0.0	Fixed
Hypertension	10	207 of 2122	47 of 1675	3.06 (2.22–4.24)	<0.001	43.4	Fixed
Neutropenia	10	503 of 2063	289 of 1625	1.37 (1.21–1.56)	<0.001	23.8	Fixed
Thrombocytopenia	8	229 of 1973	86 of 1532	1.80 (1.43–2.27)	<0.001	0.0	Fixed
Vomiting	7	69 of 1163	40 of 816	1.13 (0.77–1.66)	0.524	0.0	Fixed
Nausea	6	37 of 663	16 of 458	1.35 (0.76–2.39)	0.300	0.0	Fixed
Anemia	6	82 of 392	82 of 372	0.96 (0.75–1.23)	0.741	49.3	Fixed
Anorexia	5	24 of 416	10 of 420	2.37 (1.17–4.79)	0.016	0.0	Fixed
Leukopenia	4	62 of 275	25 of 190	1.63 (1.09–2.43)	0.017	0.0	Fixed
Sensory neuropathy	3	63 of 914	76 of 915	0.83 (0.60–1.14)	0.252	22.6	Fixed
Abdominal pain	3	6 of 136	6 of 143	1.02 (0.37–2.83)	0.967	0.0	Fixed
Stomatitis	2	7 of 158	0 of 158	8,11 (1.01–65.31)	0.049	0.0	Fixed
Hand-foot syndrome	2	23 of 626	5 of 481	3.44 (1.31–9.03)	0.012	0.0	Fixed
Venous thromboembolism	2	14 of 455	14 of 429	2.64 (0.71–9.75)	0.146	0.0	Fixed